Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Get Wall Street's Hottest Chart Every Morning Medicare ... by Medicare or other insurance plans for weight loss. In December, the FDA approved Zepbound as the first and only prescription medicine ...

The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year forecast. Monitor these key price levels.

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

When it comes to estimating the ideal semaglutide dose for weight loss, a typical Ozempic dosing chart is as follows ... Tirzepatide, sold as Mounjaro and Zepbound, is another GLP-1 agonist ...

Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.